Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?

Sensei Biotherapeutics (NASDAQ:SNSE) stock is falling on Friday after it failed to impress investors with its latest Phase 1/2 clinical trial data for SNS-101. SNS-101 is a human monoclonal antibody targeting the immune checkpoint VISTA. The company notes this has it being developed to treat solid cancer tumors. SNSE stock is down 39.8% as of Friday morning. However, shares were up 83.5% year-to-date when markets closed yesterday. Investors looking for more of the most recent stock market stories are in luc ...